616 results on '"Van Laere, Koen"'
Search Results
2. In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol
- Author
-
Vanderlinden, Greet, Carron, Charles, Vandenberghe, Rik, Vandenbulcke, Mathieu, and Van Laere, Koen
- Published
- 2024
- Full Text
- View/download PDF
3. Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
- Author
-
Luckett, Emma S., Zielonka, Magdalena, Kordjani, Amine, Schaeverbeke, Jolien, Adamczuk, Katarzyna, De Meyer, Steffi, Van Laere, Koen, Dupont, Patrick, Cleynen, Isabelle, and Vandenberghe, Rik
- Published
- 2023
- Full Text
- View/download PDF
4. Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer
- Author
-
Gebruers, Juanito, Elst, Laura, Baldewijns, Marcella, De Wever, Liesbeth, Van Laere, Koen, Albersen, Maarten, and Goffin, Karolien
- Published
- 2023
- Full Text
- View/download PDF
5. Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
- Author
-
Luckett, Emma S., Schaeverbeke, Jolien, De Meyer, Steffi, Adamczuk, Katarzyna, Van Laere, Koen, Dupont, Patrick, and Vandenberghe, Rik
- Published
- 2023
- Full Text
- View/download PDF
6. Evaluating the pharmacodynamic effects of padsevonil in healthy volunteers using simultaneous [11C]-UCB-J PET and MR Arterial Spin Labeling measurements
- Author
-
Koole, Michel, Lacroix, Brigitte, Tang, Chunmeng, Chanteux, Hugues, Maguire, Ralph Paul, and Van Laere, Koen
- Published
- 2023
- Full Text
- View/download PDF
7. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid-PET
- Author
-
De Meyer, Steffi, primary, Schaeverbeke, Jolien M, additional, Luckett, Emma S, additional, Reinartz, Mariska, additional, Blujdea, Elena R, additional, Cleynen, Isabelle, additional, Dupont, Patrick, additional, Van Laere, Koen, additional, Vanbrabant, Jeroen, additional, Stoops, Erik, additional, Vanmechelen, Eugeen, additional, di Molfetta, Guglielmo, additional, Zetterberg, Henrik, additional, Ashton, Nicholas J, additional, Teunissen, Charlotte E, additional, Poesen, Koen, additional, and Vandenberghe, Rik, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Synaptic density changes following electroconvulsive therapy: A longitudinal pilot study with PET-MR 11C-UCB-J imaging in late-life depression
- Author
-
Laroy, Maarten, primary, Vande Casteele, Thomas, additional, Van Cauwenberge, Margot, additional, Koole, Michel, additional, Dupont, Patrick, additional, Sunaert, Stefan, additional, Van den Stock, Jan, additional, Sienaert, Pascal, additional, Van Laere, Koen, additional, Vandenbulcke, Mathieu, additional, Emsell, Louise, additional, and Bouckaert, Filip, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Regional accuracy of ZTE-based attenuation correction in static and dynamic brain PET/MR
- Author
-
Schramm, Georg, Koole, Michel, Willekens, Stefanie M. A., Rezaei, Ahmadreza, Van Weehaeghe, Donatienne, Delso, Gaspar, Peeters, Ronald, Mertens, Nathalie, Nuyts, Johan, and Van Laere, Koen
- Subjects
Physics - Medical Physics - Abstract
Accurate MR-based attenuation correction (MRAC) is essential for quantitative PET/MR imaging of the brain. In this study, we analyze the regional bias caused by MRAC based on Zero-Echo-Time MR images (ZTEAC) compared to CT-based AC (CTAC) in static and dynamic PET imaging. In addition the results are compared to the performance of the current default Atlas-based AC (AtlasAC) implemented in the GE SIGNA PET/MR. Methods: Thirty static [18F]FDG and 11 dynamic [18}F]PE2I acquisitions from a GE SIGNA PET/MR were reconstructed using ZTEAC (using a research tool, GE Healthcare), single-subject AtlasAC (the current default AC in GE's SIGNA PET/MR) and CTAC (from a PET/CT acquisition of the same day). In the 30 static [18F]FDG reconstructions, the bias caused by ZTEAC and AtlasAC in the mean uptake of 85 anatomical volumes of interest (VOIs) of the Hammers' atlas was analyzed in PMOD. For the 11 dynamic [18}F]PE2I reconstructions, the bias caused by ZTEAC and AtlasAC in the non displaceable binding potential BPnd in the striatum was calculated with cerebellum as the reference region and a simplified reference tissue model. Results: The regional bias caused by ZTEAC in the static [18F]FDG reconstructions ranged from -8.0% to +7.7% (mean 0.1%, SD 2.0%). For AtlasAC this bias ranged from -31.6% to +16.6% (mean -0.4%, SD 4.3%). The bias caused by AtlasAC showed a clear gradient in the cranio-caudal direction (-4.2% in the cerebellum, +6.6% in the left superior frontal gyrus). The bias in the striatal BPnd for the [18F]PE2I reconstructions ranged from -0.8% to +4.8% (mean 1.5%, SD 1.4%) using ZTEAC and from -0.6% to +9.4% using AtlasAC (mean 4.2%, SD 2.6%). Conclusion: ZTEAC provides excellent quantitative accuracy for static and dynamic brain PET/MR, comparable to CTAC, and is clearly superior to the default AtlasAC currently implemented in the GE SIGNA PET/MR., Comment: 23 pages in total, 7 figures, 1 table, 3 supplementary figures, 5 supplementary tables
- Published
- 2018
- Full Text
- View/download PDF
10. Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
- Author
-
Luckett, Emma S., Abakkouy, Yasmina, Reinartz, Mariska, Adamczuk, Katarzyna, Schaeverbeke, Jolien, Verstockt, Sare, De Meyer, Steffi, Van Laere, Koen, Dupont, Patrick, Cleynen, Isabelle, and Vandenberghe, Rik
- Published
- 2022
- Full Text
- View/download PDF
11. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
- Author
-
Deleu, Anne-Leen, Laenen, Annouschka, Decaluwé, Herbert, Weynand, Birgit, Dooms, Christophe, De Wever, Walter, Jentjens, Sander, Goffin, Karolien, Vansteenkiste, Johan, Van Laere, Koen, De Leyn, Paul, Nackaerts, Kristiaan, and Deroose, Christophe M.
- Published
- 2022
- Full Text
- View/download PDF
12. Simultaneous 18F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use
- Author
-
Van Laere, Koen, Ceccarini, Jenny, Gebruers, Juanito, Goffin, Karolien, and Boon, Elizabet
- Published
- 2022
- Full Text
- View/download PDF
13. Simplified Edinburgh and modified Boston criteria in relation to amyloid PET for lobar intracerebral hemorrhage
- Author
-
Michiels, Laura, Dobbels, Laurens, Demeestere, Jelle, Demaerel, Philippe, Van Laere, Koen, and Lemmens, Robin
- Published
- 2022
- Full Text
- View/download PDF
14. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Tijms, Betty M, Fagan, Anne M, Hansson, Oskar, Klunk, William E, van der Flier, Wiesje M, Villemagne, Victor L, Frisoni, Giovanni B, Fleisher, Adam S, Lleó, Alberto, Mintun, Mark A, Wallin, Anders, Engelborghs, Sebastiaan, Na, Duk L, Chételat, Gäel, Molinuevo, José Luis, Landau, Susan M, Mattsson, Niklas, Kornhuber, Johannes, Sabri, Osama, Rowe, Christopher C, Parnetti, Lucilla, Popp, Julius, Fladby, Tormod, Jagust, William J, Aalten, Pauline, Lee, Dong Young, Vandenberghe, Rik, de Oliveira, Catarina Resende, Kapaki, Elisabeth, Froelich, Lutz, Ivanoiu, Adrian, Gabryelewicz, Tomasz, Verbeek, Marcel M, Sanchez-Juan, Páscual, Hildebrandt, Helmut, Camus, Vincent, Zboch, Marzena, Brooks, David J, Drzezga, Alexander, Rinne, Juha O, Newberg, Andrew, de Mendonça, Alexandre, Sarazin, Marie, Rabinovici, Gil D, Madsen, Karine, Kramberger, Milica G, Nordberg, Agneta, Mok, Vincent, Mroczko, Barbara, Wolk, David A, Meyer, Philipp T, Tsolaki, Magda, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Blennow, Kaj, van Buchem, Mark A, Cavedo, Enrica, Chen, Kewei, Chipi, Elena, Cohen, Ann D, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S, Freund-Levi, Yvonne, Gkatzima, Olymbia, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Johannsen, Peter, Klimkowicz-Mrowiec, Aleksandra, Köhler, Sebastian, Koglin, Norman, van Laere, Koen, de Leon, Mony, Lisetti, Viviana, Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M, Morris, John C, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Perera, Gayan, Peters, Oliver, and Ramakers, Inez HGB
- Subjects
Health Services and Systems ,Health Sciences ,Acquired Cognitive Impairment ,Alzheimer's Disease Related Dementias (ADRD) ,Neurosciences ,Aging ,Dementia ,Brain Disorders ,Behavioral and Social Science ,Neurodegenerative ,Alzheimer's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Mental health ,Aged ,Alzheimer Disease ,Amyloid beta-Peptides ,Brain ,Cognition Disorders ,Cognitive Dysfunction ,Cross-Sectional Studies ,Female ,Humans ,Male ,Memory ,Episodic ,Mental Status and Dementia Tests ,Middle Aged ,Positron-Emission Tomography ,Reference Values ,Amyloid Biomarker Study Group ,Other Medical and Health Sciences ,Psychology ,Cognitive Sciences ,Clinical sciences ,Clinical and health psychology - Abstract
ImportanceCerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.ObjectiveTo investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.Design, setting, and participantsThis cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Main outcomes and measuresGlobal cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.ResultsAmong 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P
- Published
- 2018
15. Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis
- Author
-
Blockmans, Daniel, primary, Moreel, Lien, additional, Betrains, Albrecht, additional, Vanderschueren, Steven, additional, Coudyzer, Walter, additional, Boeckxstaens, Lennert, additional, and Van Laere, Koen, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Age-related GABAergic differences in the primary sensorimotor cortex: A multimodal approach combining PET, MRS and TMS
- Author
-
Cuypers, Koen, Hehl, Melina, van Aalst, June, Chalavi, Sima, Mikkelsen, Mark, Van Laere, Koen, Dupont, Patrick, Mantini, Dante, and Swinnen, Stephan P.
- Published
- 2021
- Full Text
- View/download PDF
17. Approximating anatomically-guided PET reconstruction in image space using a convolutional neural network
- Author
-
Schramm, Georg, Rigie, David, Vahle, Thomas, Rezaei, Ahmadreza, Van Laere, Koen, Shepherd, Timothy, Nuyts, Johan, and Boada, Fernando
- Published
- 2021
- Full Text
- View/download PDF
18. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
- Author
-
Sanchez-Felipe, Lorena, Vercruysse, Thomas, Sharma, Sapna, Ma, Ji, Lemmens, Viktor, Van Looveren, Dominique, Arkalagud Javarappa, Mahadesh Prasad, Boudewijns, Robbert, Malengier-Devlies, Bert, Liesenborghs, Laurens, Kaptein, Suzanne J. F., De Keyzer, Carolien, Bervoets, Lindsey, Debaveye, Sarah, Rasulova, Madina, Seldeslachts, Laura, Li, Li-Hsin, Jansen, Sander, Yakass, Michael Bright, Verstrepen, Babs E., Böszörményi, Kinga P., Kiemenyi-Kayere, Gwendoline, van Driel, Nikki, Quaye, Osbourne, Zhang, Xin, ter Horst, Sebastiaan, Mishra, Niraj, Deboutte, Ward, Matthijnssens, Jelle, Coelmont, Lotte, Vandermeulen, Corinne, Heylen, Elisabeth, Vergote, Valentijn, Schols, Dominique, Wang, Zhongde, Bogers, Willy, Kuiken, Thijs, Verschoor, Ernst, Cawthorne, Christopher, Van Laere, Koen, Opdenakker, Ghislain, Vande Velde, Greetje, Weynand, Birgit, Teuwen, Dirk E., Matthys, Patrick, Neyts, Johan, Jan Thibaut, Hendrik, and Dallmeier, Kai
- Published
- 2021
- Full Text
- View/download PDF
19. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.
- Author
-
Wang, Jie, Huang, Qi, He, Kun, Li, Junpeng, Guo, Tengfei, Yang, Yang, Lin, Zengping, Li, Songye, Vanderlinden, Greet, Huang, Yiyun, Van Laere, Koen, Guan, Yihui, Guo, Qihao, Ni, Ruiqing, Li, Binying, and Xie, Fang
- Abstract
INTRODUCTION: Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the pathophysiological mechanism of Alzheimer's disease (AD). METHODS: Ten cognitively impaired (CI) individuals and 10 healthy controls (HCs) underwent [18F]SynVesT‐1 and [18F]PSS232 positron emission tomography (PET)/magnetic resonance to assess synaptic density and mGluR5 availability. The associations between mGluR5 availability and synaptic density were examined. A mediation analysis was performed to investigate the possible mediating effects of mGluR5 availability and synaptic loss on the relationship between amyloid deposition and cognition. RESULTS: CI patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs. Regional synaptic density was closely associated with regional mGluR5 availability. mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and cognition. CONCLUSIONS: Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD and are closely linked. Highlights: Cognitively impaired patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs.Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD.Regional synaptic density was closely associated with regional mGluR5 availability.mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and global cognition.With further research, modulating mGluR5 availability might be a potential therapeutic strategy for improving synaptic function in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor
- Author
-
Ivanisevic, Tonci, primary, Steklov, Mikhail, additional, Lechat, Benoit, additional, Cawthorne, Christopher, additional, Gsell, Willy, additional, Velde, Greetje Vande, additional, Deroose, Christophe, additional, Van Laere, Koen, additional, Himmelreich, Uwe, additional, Sewduth, Raj N, additional, and Sablina, Anna A, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression
- Author
-
Takamiya, Akihiro, Vande Casteele, Thomas, Koole, Michel, De Winter, François-Laurent, Bouckaert, Filip, Van den Stock, Jan, Sunaert, Stefan, Dupont, Patrick, Vandenberghe, Rik, Van Laere, Koen, Vandenbulcke, Mathieu, and Emsell, Louise
- Published
- 2021
- Full Text
- View/download PDF
22. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
- Author
-
Cawthorne, Christopher, Maguire, Paul, Mercier, Joel, Sciberras, David, Serdons, Kim, Bormans, Guy, de Hoon, Jan, Van Laere, Koen, and Koole, Michel
- Published
- 2021
- Full Text
- View/download PDF
23. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults
- Author
-
Schaeverbeke, Jolien M., Gabel, Silvy, Meersmans, Karen, Luckett, Emma S., De Meyer, Steffi, Adamczuk, Katarzyna, Nelissen, Natalie, Goovaerts, Valerie, Radwan, Ahmed, Sunaert, Stefan, Dupont, Patrick, Van Laere, Koen, and Vandenberghe, Rik
- Published
- 2021
- Full Text
- View/download PDF
24. The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: study protocol
- Author
-
Emsell, Louise, Laroy, Maarten, Van Cauwenberge, Margot, Vande Casteele, Thomas, Vansteelandt, Kristof, Van Laere, Koen, Sunaert, Stefan, Van den Stock, Jan, Bouckaert, Filip, and Vandenbulcke, Mathieu
- Published
- 2021
- Full Text
- View/download PDF
25. Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function
- Author
-
Mertens, Nathalie, Schmidt, Mark E., Hijzen, Anja, Van Weehaeghe, Donatienne, Ravenstijn, Paulien, Depre, Marleen, de Hoon, Jan, Van Laere, Koen, and Koole, Michel
- Published
- 2021
- Full Text
- View/download PDF
26. Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
- Author
-
Ahmadi Bidakhvidi, Niloefar, Laenen, Annouschka, Jentjens, Sander, Deroose, Christophe M., Van Laere, Koen, De Wever, Liesbeth, Mai, Cindy, Berghen, Charlien, De Meerleer, Gert, Haustermans, Karin, Joniau, Steven, Everaerts, Wouter, and Goffin, Karolien
- Published
- 2021
- Full Text
- View/download PDF
27. Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study
- Author
-
Michiels, Laura, Mertens, Nathalie, Thijs, Liselot, Radwan, Ahmed, Sunaert, Stefan, Vandenbulcke, Mathieu, Verheyden, Geert, Koole, Michel, Van Laere, Koen, and Lemmens, Robin
- Published
- 2022
- Full Text
- View/download PDF
28. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Knol, Dirk L, Tijms, Betty M, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Bibeau, Kristen, Blennow, Kaj, Brooks, David J, van Buchem, Mark A, Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D, Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M, Fladby, Tormod, Fleisher, Adam S, van der Flier, Wiesje M, Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S, Freund-Levi, Yvonne, Frisoni, Giovanni B, Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J, Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E, Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G, Van Laere, Koen, Landau, Susan M, Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, de Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T, Mintun, Mark A, Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M, Morris, John C, Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L, Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D, Ramakers, Inez HGB, Rami, Lorena, de Oliveira, Catarina Resende, Rinne, Juha O, Rodrigue, Karen M, and Rodríguez-Rodríguez, Eloy
- Subjects
Health Services and Systems ,Health Sciences ,Clinical Research ,Alzheimer's Disease ,Vascular Cognitive Impairment/Dementia ,Acquired Cognitive Impairment ,Neurosciences ,Alzheimer's Disease Related Dementias (ADRD) ,Brain Disorders ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Cerebrovascular ,Neurodegenerative ,Prevention ,Dementia ,Aging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Biomarkers ,Brain ,Cerebrospinal Fluid ,Cognitive Dysfunction ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid Biomarker Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceCerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).Data sourcesRelevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.Study selectionStudies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.Data extraction and synthesisIndividual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.Main outcomes and measuresPrevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.ResultsThe prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.Conclusions and relevanceAmong persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
- Published
- 2015
29. Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
- Author
-
Ossenkoppele, Rik, Jansen, Willemijn J, Rabinovici, Gil D, Knol, Dirk L, van der Flier, Wiesje M, van Berckel, Bart NM, Scheltens, Philip, Visser, Pieter Jelle, Verfaillie, Sander CJ, Zwan, Marissa D, Adriaanse, Sofie M, Lammertsma, Adriaan A, Barkhof, Frederik, Jagust, William J, Miller, Bruce L, Rosen, Howard J, Landau, Susan M, Villemagne, Victor L, Rowe, Christopher C, Lee, Dong Y, Na, Duk L, Seo, Sang W, Sarazin, Marie, Roe, Catherine M, Sabri, Osama, Barthel, Henryk, Koglin, Norman, Hodges, John, Leyton, Cristian E, Vandenberghe, Rik, van Laere, Koen, Drzezga, Alexander, Forster, Stefan, Grimmer, Timo, Sánchez-Juan, Pascual, Carril, Jose M, Mok, Vincent, Camus, Vincent, Klunk, William E, Cohen, Ann D, Meyer, Philipp T, Hellwig, Sabine, Newberg, Andrew, Frederiksen, Kristian S, Fleisher, Adam S, Mintun, Mark A, Wolk, David A, Nordberg, Agneta, Rinne, Juha O, Chételat, Gaël, Lleo, Alberto, Blesa, Rafael, Fortea, Juan, Madsen, Karine, Rodrigue, Karen M, and Brooks, David J
- Subjects
Health Services and Systems ,Health Sciences ,Genetics ,Acquired Cognitive Impairment ,Clinical Research ,Neurodegenerative ,Alzheimer's Disease ,Brain Disorders ,Aging ,Biomedical Imaging ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Brain ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid PET Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceAmyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.Data sourcesThe MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Study selectionCase reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data extraction and synthesisData were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Main outcomes and measuresEstimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.ResultsThe likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P
- Published
- 2015
30. Tau Pathology Associated With Parkinsonism and Mutation of Mitochondrial DNA Helicase Gene TWNK
- Author
-
Vandenberghe, Wim, Imberechts, Dorien, Van Laere, Koen, Jannis, Levi, De Hertogh, Gert, Ronisz, Alicja, and Thal, Dietmar Rudolf
- Published
- 2021
- Full Text
- View/download PDF
31. Tau Imaging in Late Traumatic Brain Injury: A [18F]MK-6240 Positron Emission Tomography Study.
- Author
-
Vanderlinden, Greet, Michiels, Laura, Koole, Michel, Lemmens, Robin, Liessens, Dirk, Van Walleghem, Jan, Depreitere, Bart, Vandenbulcke, Mathieu, and Van Laere, Koen
- Published
- 2024
- Full Text
- View/download PDF
32. Multiplex core of the human brain using structural, functional and metabolic connectivity derived from hybrid PET-MR imaging
- Author
-
Devrome, Martijn, primary, Van Laere, Koen, additional, and Koole, Michel, additional
- Published
- 2023
- Full Text
- View/download PDF
33. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
- Author
-
Boudewijns, Robbert, Thibaut, Hendrik Jan, Kaptein, Suzanne J. F., Li, Rong, Vergote, Valentijn, Seldeslachts, Laura, Van Weyenbergh, Johan, De Keyzer, Carolien, Bervoets, Lindsey, Sharma, Sapna, Liesenborghs, Laurens, Ma, Ji, Jansen, Sander, Van Looveren, Dominique, Vercruysse, Thomas, Wang, Xinyu, Jochmans, Dirk, Martens, Erik, Roose, Kenny, De Vlieger, Dorien, Schepens, Bert, Van Buyten, Tina, Jacobs, Sofie, Liu, Yanan, Martí-Carreras, Joan, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Delang, Leen, Rocha-Pereira, Joana, Coelmont, Lotte, Chiu, Winston, Leyssen, Pieter, Heylen, Elisabeth, Schols, Dominique, Wang, Lanjiao, Close, Lila, Matthijnssens, Jelle, Van Ranst, Marc, Compernolle, Veerle, Schramm, Georg, Van Laere, Koen, Saelens, Xavier, Callewaert, Nico, Opdenakker, Ghislain, Maes, Piet, Weynand, Birgit, Cawthorne, Christopher, Vande Velde, Greetje, Wang, Zhongde, Neyts, Johan, and Dallmeier, Kai
- Published
- 2020
- Full Text
- View/download PDF
34. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report
- Author
-
Haemels, Maarten, Delaunoit, Thierry, Van Laere, Koen, Van Cutsem, Eric, Verslype, Chris, and Deroose, Christophe M.
- Published
- 2020
- Full Text
- View/download PDF
35. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
- Author
-
Caprioglio, Camilla, Ribaldi, Federica, Visser, Leonie N. C., Minguillon, Carolina, Collij, Lyduine E., Grau-Rivera, Oriol, Zeyen, Philip, Molinuevo, José Luis, Gispert, Juan Domingo, Garibotto, Valentina, Moro, Christian, Walker, Zuzana, Edison, Paul, Demonet, Jean-François, Barkhof, Frederik, Scheltens, Philip, Alves, Isadora Lopes, Gismondi, Rossella, Farrar, Gill, Stephens, Andrew W., Jessen, Frank, Frisoni, Giovanni B., Altomare, Daniele, Abdelnour, Carla, Aguilera, Nuria, Aksman, Leon, Alarcón-Martín, Emilio, Alegret, Montse, Alonso-Lana, Silvia, Andersen, Pia, Arab, Majd, Aspö, Malin, Bader, Ilona, Bader, Ilse, Banton, Nigel, Barnes, Rodrigo, Barrie, Dawn, Battle, Mark, Belén Collado, Ana, Bellet, Julie, Berkhof, Johannes, Biger, Marine, Birck, Cindy, Bischof, Gerard, Boada, Mercè, Boellaard, Ronald, Bogdanovic, Nenad, Bollack, Ariane, Bombois, Stéphanie, Borg, Stefan, Borjesson-Hanson, Anne, Boskov, Vladimir, Boutantin, Justine, Boutoleau-Bretonniere, Claire, Bouwman, Femke, Breuilh, Laetitia, Bringman, Eva, Brunel, Baptiste, Bucci, Marco, Buckley, Chris, Buendía, Mar, Bullich, Santi, Calvet, Anna, Cañada, Laia, Cañada, Marta, Cardoso, Jorge, Carlier, Jasmine, Carre, Elise, Carrie, Isabelle, Cassagnaud, Pascaline, Cassol, Emmanuelle, Castilla-Martí, Miguel, Cazalon, Elodie, Chaarriau, Tiphaine, Chaigeau, Rachel, Chalmers, Taylor, Clerc, Marie-Thérèse, Clerigue, Montserrat, Cognat, Emmanuel, Coll, Nina, Collij, Lyduine E, Connely, Peter, Cordier, Elodie, Costes, Corine, Coulange, Camille, Courtemanche, Hélène, Creisson, Eric, Crinquette, Charlotte, Cuevas, Rosario, Cufi, Marie-Noëlle, Dardenne, Sophie, de Arriba, Maria, de Costa Luis, Casper, de Gier, Yvonne, de Verbizier Lonjon, Delphine, Dekker, Veronique, Dekyndt, Bérengère, Delbeuck, Xavier, Delrieu, Julien, Deramecourt, Vincent, Desclaux, Françoise, Diaz, Carlos, Diego, Susana, Djafar, Mehdi, Dölle, Britta, Doull, Laura, Dricot, Laurence, Drzezga, Alexander, Dubois, Bruno, Dumont, Julien, Dumur, Jean, Dumurgier, Julien, Dvorak, Martin, Ecay, Mirian, Escher, Claus, Estanga, Ainara, Esteban, Ester, Fanjaud, Guy, Fauria, Karine, Felez Sanchez, Marta, Feukam Talla, Patrick, Ford, Lisa, Frisoni, Giovanni B, Fuster, David, Gabelle, Audrey, Gaubert, Sinead, Gauci, Cédric, Geldhof, Christine, Georges, Jean, Ghika, Joseph, González, Elena, Goovaerts, Valerie, Goulart, Denis Mariano, Grasselli, Caroline, Gray, Katherine, Greensmith, Martin, Grozn, Laure, Guillemaud, Céline, Gunn, Fiona, Guntur Ramkumar, Prasad, Hagman, Göran, Hansseuw, Bernard, Heeman, Fiona, Hendriks, Janine, Himmelmann, Jakob, Hitzel, Anne, Hives, Florent, Hoenig, Merle, Hourrègue, Claire, Hudson, Justine, Huguet, Jordi, Ibarria, Marta, Iidow, Ifrah, Indart, Sandrine, Ingala, Silvia, Ivanoiu, Adrian, Jacquemont, Charlotte, Jelic, Vesna, Jiao, Jieqing, Jofresa, Sara, Jonsson, Cathrine, Kaliukhovich, Dzmitry, Kern, Silke, Kivipelto, Miia, Knezevic, Iva, Kuchcinski, Grégory, Laforce, Manon, Lafuente, Asunción, Lala, Françoise, Lammertsma, Adriaan, Lax, Michelle, Lebouvier, Thibaud, Lee, Ho-Yun, Lee, Lean, Leeuwis, Annebet, Lefort, Amandine, Legrand, Jean-François, Leroy, Mélanie, Lesoil Markowski, Constance, Levy, Marcel, Lhommel , Renaud, Lopes, Renaud, Lopes Alves, Isadora, Lorenzini, Luigi, Lorette, Adrien, Luckett, Emma, Lundin, Marie, Mackowiak, Marie-Anne, Malotaux, Vincent, Manber, Richard, Manyakov, Nikolay, Markiewicz, Pawel, Marne, Paula, Marquié, Marta, Martín, Elvira, Martínez, Joan, Martinez Lage, Pablo, Mastenbroek, Sophie E, Maureille, Aurélien, Meersmans, Karen, Mett, Anja, Milne, Joseph, Minguillón, Carolina, Modat, Marc, Montrreal, Laura, Müller, Theresa, Muniz, Graciela, Mutsarts, Henk Jan, Nilsson, Ted, Ninerola, Aida, Nordberg, Agneta, Novaes, Wilse, Nuno Carmelo Pires Silva, Joao, Operto, Greg, Orellana, Adela, Ousset, Pierre-Jean, Outteryck, Olivier, Pallardy, Amandine, Palombit, Alessandro, Pancho, Ana, Pappon, Martin, Paquet, Claire, Pariente, Jérémie, Pasquier, Florence, Payoux, Pierre, Peaker, Harry, Pelejà, Esther, Pennetier, Delphine, Pérez-Cordón, Alba, Perissinotti, Andrés, Perrenoud, Matthieu Paul, Petit, Sandrine, Petyt, Grégory, Pfeil, Julia, Pirotte, Blanche, Pla, Sandra, Plaza Wuthrich, Sonia, Poitrine, Lea, Pollet, Marianne, Poncelet, Jean-Benoit, Prior, John, Pruvo, Jean-Pierre, Putallaz, Pauline, Queneau, Mathieu, Quenon , Lisa, Rădoi, Andreea, Rafiq, Marie, Ramage, Fiona, Ramis, Maribel, Reinwald, Michael, Rios, Gonzalo, Ritchie, Craig, Rodriguez, Elena, Rollin, Adeline, Rouaud, Olivier, Sacuiu, Simona, Saint-Aubert, Laure, Sala, Arianna, Salabert, Anne-Sophie, Saldias, Jon, Salvadó, Gemma, Sanabria, Angela, Sannemann, Lena, Sastre, Nathalie, Savina, Daniela, Savitcheva, Irina, Schaeverbeke, Jolien, Schildermans, Carine, Schmidt, Mark, Schöll, Michael, Schuermans, Jeroen, Semah, Franck, Shekari, Mahnaz, Skoog, Ingmar, Sotolongo-Grau, Oscar, Stephens, Andrew, Stewart, Tiffany, Stutzmann, Jennyfer, Tait, Murray, Tárraga, Lluis, Tartari, Juan Pablo, Tysen-backstrom, Ann-christine, Valero, Sergi, Vallez Garcia, David, van Berckel, Bart N M, van Essen, Martijn, Van Laere, Koen, van Leur, Jeroen, van Maurik, Ingrid S, Vandenberghe, Rik, Vellas, Bruno, Virolinen, Jukka, Visser, Pieter Jelle, Walles, Håkan, Wallin, Emilia, Whitelaw, Grant, Wimberley, Catriona, Win , Zarni, Wink, Alle Meije, Wolz, Robin, Woodside, John, Yaqub, Maqsood, Zettergren, Anna, Medical Psychology, APH - Personalized Medicine, APH - Quality of Care, Radiology and nuclear medicine, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neuroinfection & -inflammation, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, Neurology, Dekyndt, Bérengère, Delbeuck, Xavier, Delrieu, Julien, Demonet, Jean-François, Deramecourt, Vincent, Desclaux, Françoise, Diaz, Carlos, Diego, Susana, Djafar, Mehdi, Dölle, Britta, Doull, Laura, Dricot, Laurence, Drzezga, Alexander, Dubois, Bruno, Dumont, Julien, Dumur, Jean, Dumurgier, Julien, Dvorak, Martin, Ecay, Mirian, Edison, Paul, Escher, Claus, Estanga, Ainara, Esteban, Ester, Fanjaud, Guy, Farrar, Gill, Fauria, Karine, Felez Sanchez, Marta, Feukam Talla, Patrick, Ford, Lisa, Frisoni, Giovanni B, Fuster, David, Gabelle, Audrey, Garibotto, Valentina, Gaubert, Sinead, Gauci, Cédric, Geldhof, Christine, Georges, Jean, Ghika, Joseph, Gismondi, Rossella, Gispert, Juan Domingo, González, Elena, Goovaerts, Valerie, Goulart, Denis Mariano, Grasselli, Caroline, Grau-Rivera, Oriol, Gray, Katherine, Greensmith, Martin, Grozn, Laure, Guillemaud, Céline, Gunn, Fiona, Guntur Ramkumar, Prasad, Hagman, Göran, Hansseuw, Bernard, Heeman, Fiona, Hendriks, Janine, Himmelmann, Jakob, Hitzel, Anne, Hives, Florent, Hoenig, Merle, Hourrègue, Claire, Hudson, Justine, Huguet, Jordi, Ibarria, Marta, Iidow, Ifrah, Indart, Sandrine, Ingala, Silvia, Ivanoiu, Adrian, Jacquemont, Charlotte, Jelic, Vesna, Jessen, Frank, Jiao, Jieqing, Jofresa, Sara, Jonsson, Cathrine, Kaliukhovich, Dzmitry, Kern, Silke, Kivipelto, Miia, Knezevic, Iva, Kuchcinski, Grégory, Laforce, Manon, Lafuente, Asunción, Lala, Françoise, Lammertsma, Adriaan, Lax, Michelle, Lebouvier, Thibaud, Lee, Ho-Yun, Lee, Lean, Leeuwis, Annebet, Lefort, Amandine, Legrand, Jean-François, Leroy, Mélanie, Lesoil Markowski, Constance, Levy, Marcel, Lhommel, Renaud, Lopes, Renaud, Lopes Alves, Isadora, Lorenzini, Luigi, Lorette, Adrien, Luckett, Emma, Lundin, Marie, Mackowiak, Marie-Anne, Malotaux, Vincent, Manber, Richard, Manyakov, Nikolay, Markiewicz, Pawel, Marne, Paula, Marquié, Marta, Martín, Elvira, Martínez, Joan, Martinez Lage, Pablo, Mastenbroek, Sophie E, Maureille, Aurélien, Meersmans, Karen, Mett, Anja, Milne, Joseph, Minguillón, Carolina, Modat, Marc, Molinuevo, José Luis, Montrreal, Laura, Moro, Christian, Müller, Theresa, Muniz, Graciela, Mutsarts, Henk Jan, Nilsson, Ted, Ninerola, Aida, Nordberg, Agneta, Novaes, Wilse, Nuno Carmelo Pires Silva, Joao, Operto, Greg, Orellana, Adela, Ousset, Pierre-Jean, Outteryck, Olivier, Pallardy, Amandine, Palombit, Alessandro, Pancho, Ana, Pappon, Martin, Paquet, Claire, Pariente, Jérémie, Pasquier, Florence, Payoux, Pierre, Peaker, Harry, Abdelnour, Carla, Pelejà, Esther, Pennetier, Delphine, Pérez-Cordón, Alba, Perissinotti, Andrés, Perrenoud, Matthieu Paul, Petit, Sandrine, Petyt, Grégory, Pfeil, Julia, Pirotte, Blanche, Pla, Sandra, Aguilera, Nuria, Plaza Wuthrich, Sonia, Poitrine, Lea, Pollet, Marianne, Poncelet, Jean-Benoit, Prior, John, Pruvo, Jean-Pierre, Putallaz, Pauline, Queneau, Mathieu, Quenon, Lisa, Rădoi, Andreea, Aksman, Leon, Rafiq, Marie, Ramage, Fiona, Ramis, Maribel, Reinwald, Michael, Rios, Gonzalo, Ritchie, Craig, Rodriguez, Elena, Rollin, Adeline, Rouaud, Olivier, Sacuiu, Simona, Alarcón-Martín, Emilio, Saint-Aubert, Laure, Sala, Arianna, Salabert, Anne-Sophie, Saldias, Jon, Salvadó, Gemma, Sanabria, Angela, Sannemann, Lena, Sastre, Nathalie, Savina, Daniela, Savitcheva, Irina, Alegret, Montse, Schaeverbeke, Jolien, Scheltens, Philip, Schildermans, Carine, Schmidt, Mark, Schöll, Michael, Schuermans, Jeroen, Semah, Franck, Shekari, Mahnaz, Skoog, Ingmar, Sotolongo-Grau, Oscar, Alonso-Lana, Silvia, Stephens, Andrew, Stewart, Tiffany, Stutzmann, Jennyfer, Tait, Murray, Tárraga, Lluis, Tartari, Juan Pablo, Tysen-Backstrom, Ann-Christine, Valero, Sergi, Vallez Garcia, David, van Berckel, Bart N M, Altomare, Daniele, van Essen, Martijn, Van Laere, Koen, van Leur, Jeroen, van Maurik, Ingrid S, Vandenberghe, Rik, Vellas, Bruno, Virolinen, Jukka, Visser, Pieter Jelle, Walker, Zuzana, Walles, Håkan, Andersen, Pia, Wallin, Emilia, Whitelaw, Grant, Wimberley, Catriona, Win, Zarni, Wink, Alle Meije, Wolz, Robin, Woodside, John, Yaqub, Maqsood, Zettergren, Anna, Zeyen, Philip, Arab, Majd, Aspö, Malin, Bader, Ilona, Bader, Ilse, Banton, Nigel, Barkhof, Frederik, Barnes, Rodrigo, Barrie, Dawn, Battle, Mark, Belén Collado, Ana, Bellet, Julie, Berkhof, Johannes, Biger, Marine, Birck, Cindy, Bischof, Gerard, Boada, Mercè, Boellaard, Ronald, Bogdanovic, Nenad, Bollack, Ariane, Bombois, Stéphanie, Borg, Stefan, Borjesson-Hanson, Anne, Boskov, Vladimir, Boutantin, Justine, Boutoleau-Bretonniere, Claire, Bouwman, Femke, Breuilh, Laetitia, Bringman, Eva, Brunel, Baptiste, Bucci, Marco, Buckley, Chris, Buendía, Mar, Bullich, Santi, Calvet, Anna, Cañada, Laia, Cañada, Marta, Caprioglio, Camilla, Cardoso, Jorge, Carlier, Jasmine, Carre, Elise, Carrie, Isabelle, Cassagnaud, Pascaline, Cassol, Emmanuelle, Castilla-Martí, Miguel, Cazalon, Elodie, Chaarriau, Tiphaine, Chaigeau, Rachel, Chalmers, Taylor, Clerc, Marie-Thérèse, Clerigue, Montserrat, Cognat, Emmanuel, Coll, Nina, Collij, Lyduine E, Connely, Peter, Cordier, Elodie, Costes, Corine, Coulange, Camille, Courtemanche, Hélène, Creisson, Eric, Crinquette, Charlotte, Cuevas, Rosario, Cufi, Marie-Noëlle, Dardenne, Sophie, de Arriba, Maria, de Costa Luis, Casper, de Gier, Yvonne, de Verbizier Lonjon, Delphine, and Dekker, Veronique
- Subjects
Male ,Adult ,metabolism [Brain] ,Positron-Emission Tomography ,diagnosis [Alzheimer Disease] ,diagnostic imaging [Cognitive Dysfunction] ,Humans ,metabolism [Amyloid beta-Peptides] ,ddc:610 ,Prospective Studies ,Disclosure ,General Medicine ,Aged - Abstract
ImportanceIndividuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know their amyloid status; however, the disclosure of a positive amyloid-PET result might have psychological risks.ObjectiveTo assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive.Design, Setting, and ParticipantsThis prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022.ExposuresDisclosure of amyloid-PET result.Main Outcomes and MeasuresPsychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale–Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms).ResultsAfter disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30]) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2]; P P P P P = .06) and Depression (–1.0 [–2.0 to 0.0] vs –1.0 [–3.0 to 0.0]; P = .46) deltas (score after disclosure – scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = –0.43; P = .02) whereas the presence of study partner was associated with higher disclosure-related distress (W = 7.5; P = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up.Conclusions and RelevanceThe disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern.
- Published
- 2023
36. Correction: Schroyen et al. Neuroinflammation and Its Association with Cognition, Neuronal Markers and Peripheral Inflammation after Chemotherapy for Breast Cancer. Cancers 2021, 13, 4198
- Author
-
Schroyen, Gwen, primary, Blommaert, Jeroen, additional, van Weehaeghe, Donatienne, additional, Sleurs, Charlotte, additional, Vandenbulcke, Mathieu, additional, Dedoncker, Nina, additional, Hatse, Sigrid, additional, Goris, An, additional, Koole, Michel, additional, Smeets, Ann, additional, van Laere, Koen, additional, Sunaert, Stefan, additional, and Deprez, Sabine, additional
- Published
- 2023
- Full Text
- View/download PDF
37. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
- Author
-
Boeckxstaens, Lennert, primary, Pauwels, Elin, additional, Vandecaveye, Vincent, additional, Deckers, Wies, additional, Cleeren, Frederik, additional, Dekervel, Jeroen, additional, Vandamme, Timon, additional, Serdons, Kim, additional, Koole, Michel, additional, Bormans, Guy, additional, Laenen, Annouschka, additional, Clement, Paul M., additional, Geboes, Karen, additional, Van Cutsem, Eric, additional, Nackaerts, Kristiaan, additional, Stroobants, Sigrid, additional, Verslype, Chris, additional, Van Laere, Koen, additional, and Deroose, Christophe M., additional
- Published
- 2023
- Full Text
- View/download PDF
38. Long-term Ashtanga yoga practice decreases medial temporal and brainstem glucose metabolism in relation to years of experience
- Author
-
van Aalst, June, Ceccarini, Jenny, Schramm, Georg, Van Weehaeghe, Donatienne, Rezaei, Ahmadreza, Demyttenaere, Koen, Sunaert, Stefan, and Van Laere, Koen
- Published
- 2020
- Full Text
- View/download PDF
39. Role of the GLUT1 Glucose Transporter in Postnatal CNS Angiogenesis and Blood-Brain Barrier Integrity
- Author
-
Veys, Koen, Fan, Zheng, Ghobrial, Moheb, Bouché, Ann, García-Caballero, Melissa, Vriens, Kim, Conchinha, Nadine Vasconcelos, Seuwen, Aline, Schlegel, Felix, Gorski, Tatiane, Crabbé, Melissa, Gilardoni, Paola, Ardicoglu, Raphaela, Schaffenrath, Johanna, Casteels, Cindy, De Smet, Gino, Smolders, Ilse, Van Laere, Koen, Abel, E. Dale, Fendt, Sarah-Maria, Schroeter, Aileen, Kalucka, Joanna, Cantelmo, Anna Rita, Wälchli, Thomas, Keller, Annika, Carmeliet, Peter, and De Bock, Katrien
- Published
- 2020
- Full Text
- View/download PDF
40. Prospective comparison of [F-18]AlF-NOTA-octreotide PET/MRI to [Ga-68]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
- Author
-
Boeckxstaens, Lennert, Pauwels, Elin, Vandecaveye, Vincent, Deckers, Wies, Cleeren, Frederik, Dekervel, Jeroen, Vandamme, Timon, Serdons, Kim, Koole, Michel, Bormans, Guy, Laenen, Annouschka, Clement, Paul M, Geboes, Karen, Van Cutsem, Eric, Nackaerts, Kristiaan, Stroobants, Sigrid, Verslype, Chris, Van Laere, Koen, and Deroose, Christophe M
- Subjects
PET/MR ,PET ,Neuroendocrine tumor ,[68Ga]Ga-DOTATATE ,[18F]AlF-NOTA-octreotide ,Somatostatin receptor - Abstract
BACKGROUND: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18F]AlF-OC PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18F]AlF-OC ("incremental lesions"). METHODS: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient. RESULTS: In total, 195 unique lesions were detected: 167 with [68Ga]Ga-DOTATATE and 193 with [18F]AlF-OC. The DR for [18F]AlF-OC was 99.1% versus 91.4% for [68Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18F]AlF-OC, of which 91% were confirmed by MRI and considered true positives. CONCLUSION: The DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta. CLINICALTRIALS: gov/study/NCT04552847. ispartof: EJNMMI RESEARCH vol:13 issue:1 ispartof: location:Germany status: published
- Published
- 2023
41. Differences in Cerebral Glucose Metabolism in ALS Patients with and without C9orf72 and SOD1 Mutations
- Author
-
De Vocht, Joke, primary, Van Weehaeghe, Donatienne, additional, Ombelet, Fouke, additional, Masrori, Pegah, additional, Lamaire, Nikita, additional, Devrome, Martijn, additional, Van Esch, Hilde, additional, Moisse, Mathieu, additional, Koole, Michel, additional, Dupont, Patrick, additional, Van Laere, Koen, additional, and Van Damme, Philip, additional
- Published
- 2023
- Full Text
- View/download PDF
42. The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging
- Author
-
Dickson, John C., Tossici-Bolt, Livia, Sera, Terez, Booij, Jan, Ziebell, Morten, Morbelli, Silvia, Assenbaum-Nan, Susanne, Borght, Thierry Vander, Pagani, Marco, Kapucu, Ozlem L., Hesse, Swen, Van Laere, Koen, Darcourt, Jacques, Varrone, Andrea, and Tatsch, Klaus
- Published
- 2017
- Full Text
- View/download PDF
43. SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement
- Author
-
Botermans, Wouter, primary, Koole, Michel, additional, Van Laere, Koen, additional, Savidge, Jonathan R., additional, Kemp, John A., additional, Sunaert, Stefan, additional, Duffy, Maeve M., additional, Ramael, Steven, additional, Cesura, Andrea M., additional, D’Ostilio, Kevin, additional, Gossen, Denis, additional, Madsen, Torsten M., additional, Lodeweyckx, Thomas, additional, and de Hoon, Jan, additional
- Published
- 2023
- Full Text
- View/download PDF
44. Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI
- Author
-
Lens, Géraldine, primary, Ahmadi Bidakhvidi, Niloefar, additional, Vandecaveye, Vincent, additional, Grauwels, Steven, additional, Laenen, Annouschka, additional, Deckers, Wies, additional, Peeters, Ronald, additional, Dresen, Raphaëla C., additional, Dekervel, Jeroen, additional, Verslype, Chris, additional, Nackaerts, Kristiaan, additional, Clement, Paul M., additional, Van Cutsem, Eric, additional, Koole, Michel, additional, Goffin, Karolien, additional, Van Laere, Koen, additional, and Deroose, Christophe M., additional
- Published
- 2023
- Full Text
- View/download PDF
45. Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET
- Author
-
Shuping, Joanna L., primary, Matthews, Dawn C., additional, Adamczuk, Katarzyna, additional, Scott, David, additional, Rowe, Christopher C., additional, Kreisl, William C., additional, Johnson, Sterling C., additional, Lukic, Ana S., additional, Johnson, Keith A., additional, Rosa‐Neto, Pedro, additional, Andrews, Randolph D., additional, Van Laere, Koen, additional, Cordes, Lindsay, additional, Ward, Larry, additional, Wilde, Claire L., additional, Barakos, Jerome, additional, Purcell, Derk D., additional, Devanand, Davangere P., additional, Stern, Yaakov, additional, Luchsinger, Jose A., additional, Sur, Cyrille, additional, Price, Julie C., additional, Brickman, Adam M., additional, Klunk, William E., additional, Boxer, Adam L., additional, Mathotaarachchi, Sulantha S., additional, Lao, Patrick J., additional, and Evelhoch, Jeffrey L., additional
- Published
- 2023
- Full Text
- View/download PDF
46. Additional file 1 of Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
- Author
-
Luckett, Emma S., Zielonka, Magdalena, Kordjani, Amine, Schaeverbeke, Jolien, Adamczuk, Katarzyna, De Meyer, Steffi, Van Laere, Koen, Dupont, Patrick, Cleynen, Isabelle, and Vandenberghe, Rik
- Abstract
Additional file 1: Supplementary Figure 1. Differentially expressed genes at follow-up compared to baseline in amyloid non-accumulators. Data points are based coloured on significance: grey = non-significant, blue = non-significant but with FDR p-value < 0.05, red = significant with FDR p-value < 0.05 and log2FoldChange ± 1. N = 53. Pval on y-axis represents the uncorrected p-value < 0.05 threshold for visualisation. Supplementary Figure 2. Detection of modules using baseline expression data. (A) Scale independence and (B) mean connectivity used to derive the soft power threshold. (C) Clustering of module eigengenes, where similar clusters were merged using a cutHeight =0.25 (red line). (D) Cluster dendrogram of co-expression modules shown, both with the 28 dynamic modules (top row) and final merged 17 modules (bottom row). Supplementary Figure 3. Top 20 general cell types derived from cell-specific enrichment of the highly interconnected genes from the baseline blue WGCNA module. The genes are displayed from left to right ranked by the most significant human tissue-cell-type. The red dotted line is the Bonferronicorrected significance (p = 3.69 × 10 × 10−5) by 1355 tissue-cell types. The grey line is the nominal significance (p = 1 × 10 × 10−3). The Y-axis indicates the tissue-cell-type specificity (–log10 (combined p value)) for each tissue-cell-type from the cell-specific enrichment. Supplementary Figure 4. Detection of modules using follow-up expression data. (A) Scale independence and (B) mean connectivity used to derive the soft power threshold. (C) Clustering of module eigengenes, where similar clusters were merged using a cutHeight =0.25 (red line). (D) Cluster dendrogram of co-expression modules shown, both with the 32 dynamic modules (top row) and final merged 35 modules (bottom row). Supplementary Figure 5. Top 20 general cell types derived from cell-specific enrichment of the highly interconnected genes from the follow-up blue WGCNA module. The genes are displayed from left to right ranked by the most significant human tissue-cell-type. The red dotted line is the Bonferronicorrected significance (p = 3.69 × 10 × 10−5) by 1355 tissue-cell types. The grey line is the nominal significance (p = 1 × 10 × 10−3). The Y-axis indicates the tissue-cell-type specificity (–log10 (combined p value)) for each tissue-cell-type from the cell-specific enrichment. Supplementary Figure 6. Top 20 general cell types derived from cell-specific enrichment of the highly interconnected genes from the follow-up turquoise WCGNA module. The genes are displayed from left to right ranked by the most significant human tissue-cell-type. The red dotted line is the Bonferroni-corrected significance (p = 3.69 × 10 × 10−5) by 1355 tissue-cell types. The grey line is the nominal significance (p = 1 × 10 × 10−3). The Y-axis indicates the tissue-cell-type specificity (–log10 (combined p-value)) for each tissue-cell-type from the cell-specific enrichment. Supplementary Figure 7. Detection of modules using follow-up expression data. (A) Scale independence and mean connectivity used to derive the soft power threshold. (B) Cluster dendrogram of consensus modules.
- Published
- 2023
- Full Text
- View/download PDF
47. Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
- Author
-
Shuping, Joanna L, Matthews, Dawn C, Adamczuk, Katarzyna, Scott, David, Rowe, Christopher C, Kreisl, William C, Johnson, Sterling C, Lukic, Ana S, Johnson, Keith A, Rosa-Neto, Pedro, Andrews, Randolph D, Van Laere, Koen, Cordes, Lindsay, Ward, Larry, Wilde, Claire L, Barakos, Jerome, Purcell, Derk D, Devanand, Davangere P, Stern, Yaakov, Luchsinger, Jose A, Sur, Cyrille, Price, Julie C, Brickman, Adam M, Klunk, William E, Boxer, Adam L, Mathotaarachchi, Sulantha S, Lao, Patrick J, and Evelhoch, Jeffrey L
- Subjects
Science & Technology ,positron emission tomography ,Clinical Neurology ,Neurosciences ,visual read ,ASSOCIATION ,Alzheimer's disease ,florquinitau ,tracer ,[F-18]MK-6240 ,PATHOLOGY ,VARIABILITY ,Psychiatry and Mental health ,POSITRON-EMISSION-TOMOGRAPHY ,AGE ,neurofibrillary tangles ,Neurosciences & Neurology ,tau ,Neurology (clinical) ,Life Sciences & Biomedicine ,MK-6240 ,ALZHEIMER-DISEASE - Abstract
BACKGROUND: The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within-brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK-6240 use to identify and stage AD subjects versus non-AD and controls. METHODS: Five expert readers used their own methods to assess 30 scans of mixed diagnosis (47% cognitively normal, 23% mild cognitive impairment, 20% AD, 10% traumatic brain injury) and provided input regarding regional and global positivity, features influencing assessment, confidence, practicality, and clinical relevance. Inter-reader agreement and concordance with quantitative values were evaluated to confirm that regions could be read reliably. Guided by input regarding clinical applicability and practicality, read classifications were defined. The readers read the scans using the new classifications, establishing by majority agreement a gold standard read for those scans. Two naïve readers were trained and read the 30-scan set, providing initial validation. Inter-rater agreement was further tested by two trained independent readers in 131 scans. One of these readers used the same method to read a full, diverse database of 1842 scans; relationships between read classification, clinical diagnosis, and amyloid status as available were assessed. RESULTS: Four visual read classifications were determined: no uptake, medial temporal lobe (MTL) only, MTL and neocortical uptake, and uptake outside MTL. Inter-rater kappas were 1.0 for the naïve readers gold standard scans read and 0.98 for the independent readers 131-scan read. All scans in the full database could be classified; classification frequencies were concordant with NFT histopathology literature. DISCUSSION: This four-class [18F]MK-6240 visual read method captures the presence of medial temporal signal, neocortical expansion associated with disease progression, and atypical distributions that may reflect different phenotypes. The method demonstrates excellent trainability, reproducibility, and clinical relevance supporting clinical use. HIGHLIGHTS: A visual read method has been developed for [18F]MK-6240 tau positron emission tomography.The method is readily trainable and reproducible, with inter-rater kappas of 0.98.The read method has been applied to a diverse set of 1842 [18F]MK-6240 scans.All scans from a spectrum of disease states and acquisitions could be classified.Read classifications are consistent with histopathological neurofibrillary tangle staging literature. ispartof: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS vol:9 issue:1 ispartof: location:United States status: published
- Published
- 2023
48. Additional file 2 of Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
- Author
-
Luckett, Emma S., Zielonka, Magdalena, Kordjani, Amine, Schaeverbeke, Jolien, Adamczuk, Katarzyna, De Meyer, Steffi, Van Laere, Koen, Dupont, Patrick, Cleynen, Isabelle, and Vandenberghe, Rik
- Abstract
Additional file 2: Supplementary Table 1. APOE4 follow-up versus baseline significant differentially expressed genes. Supplementary Table 2. APOE4 non-carriers follow-up versus baseline significant differentially expressed genes. Supplementary Table 3. Cell deconvolution contributions generated using CIBERSORT. Supplementary Table 4. Amyloid non-accumulators follow-up versus baseline significant differentially expressed genes. Supplementary Table 5. Follow-up versus baseline significant differentially expressed genes in amyloid negative-positive and amyloid positive-positive individuals. Supplementary Table 6. Follow-up versus baseline significant differentially expressed genes in amyloid negative individuals. Supplementary Table 7. Direct association scores of significant differentially expressed genes at follow-up versus baseline in APOE4 carriers. Supplementary Table 8. Direct association scores of significant differentially expressed genes at follow-up versus baseline in amyloid negativepositive and amyloid positive-positive individuals. Supplementary Table 9. APOE4 carriers gene set enrichment analysis gene ontology upregulated. Supplementary Table 10. APOE4 non-carriers gene set enrichment analysis gene ontology upregulated. Supplementary Table 11. APOE4 carriers gene set enrichment analysis gene ontology downregulated. Supplementary Table 12. APOE4 non-carriers gene set enrichment analysis gene ontology downregulated. Supplementary Table 13. Amyloid non-accumulators gene set enrichment analysis gene ontology upregulated. Supplementary Table 14. Amyloid non-accumulators gene set enrichment analysis gene ontology downregulated. Supplementary Table 15. Amyloid negative-positive/positive-positive gene set enrichment analysis gene ontology upregulated. Supplementary Table 16. Amyloid negative-negative gene set enrichment analysis gene ontology upregulated. Supplementary Table 17. Amyloid negative-positive/positive-positive gene set enrichment analysis gene ontology downregulated. Supplementary Table 18. Amyloid negative-negative gene set enrichment analysis gene ontology downregulated. Supplementary Table 19. Baseline Blue module enrichment. Supplementary Table 20. Follow-up Blue module enrichment. Supplementary Table 21. Follow-up Turquoise module enrichment.
- Published
- 2023
- Full Text
- View/download PDF
49. Prospective comparison of [¹⁸F]AlF-NOTA-octreotide PET/MRI to [⁶⁸Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
- Author
-
Boeckxstaens, Lennert, Pauwels, Elin, Vandecaveye, Vincent, Deckers, Wies, Cleeren, Frederik, Dekervel, Jeroen, Vandamme, Timon, Serdons, Kim, Koole, Michel, Bormans, Guy, Laenen, Annouschka, Clement, Paul M., Geboes, Karen, Van Cutsem, Eric, Nackaerts, Kristiaan, Stroobants, Sigrid, Verslype, Chris, Van Laere, Koen, and Deroose, Christophe M.
- Subjects
Computer. Automation ,Human medicine - Abstract
Background Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [F-18]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [F-18]AlF-OC PET/CT outperforms [Ga-68]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [F-18]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [F-18]AlF-OC ("incremental lesions").Methods Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [Ga-68]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [F-18]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient.Results In total, 195 unique lesions were detected: 167 with [Ga-68]Ga-DOTATATE and 193 with [F-18]AlF-OC. The DR for [F-18]AlF-OC was 99.1% versus 91.4% for [Ga-68]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [F-18]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [F-18]AlF-OC, of which 91% were confirmed by MRI and considered true positives.Conclusion The DR of [F-18]AlF-OC was numerically higher and non-inferior to the DR of [Ga-68]Ga-DOTATATE. [F-18]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [F-18]AlF-OC as a new alternative for SSTR PET in clinical practice.
- Published
- 2023
50. Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson’s disease using 18F-FDG PET imaging
- Author
-
Devrome, Martijn, Casteels, Cindy, Van der Perren, Anke, Van Laere, Koen, Baekelandt, Veerle, and Koole, Michel
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.